Royal Bank of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target boosted by Royal Bank of Canada from $142.00 to $182.00 in a research report report published on Friday morning, Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock.

SRPT has been the subject of a number of other research reports. Oppenheimer raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 price objective for the company in a research report on Tuesday, May 14th. Wedbush reaffirmed an outperform rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a research report on Friday, May 17th. Robert W. Baird boosted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a research report on Friday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating for the company in a research report on Friday, May 3rd. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of Moderate Buy and an average target price of $184.83.

Sarepta Therapeutics Price Performance

SRPT opened at $163.85 on Friday. The company has a 50-day moving average of $126.47 and a 200-day moving average of $120.71. The company has a market capitalization of $15.49 billion, a P/E ratio of 1,489.55 and a beta of 0.96. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.44) EPS. Equities analysts expect that Sarepta Therapeutics will post 2.99 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Envestnet Asset Management Inc. lifted its stake in Sarepta Therapeutics by 152.3% during the third quarter. Envestnet Asset Management Inc. now owns 35,642 shares of the biotechnology company’s stock valued at $4,321,000 after purchasing an additional 21,514 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Sarepta Therapeutics by 26.0% during the third quarter. Hsbc Holdings PLC now owns 2,515 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 519 shares during the last quarter. Dark Forest Capital Management LP lifted its stake in Sarepta Therapeutics by 65.9% during the third quarter. Dark Forest Capital Management LP now owns 9,228 shares of the biotechnology company’s stock valued at $1,119,000 after purchasing an additional 3,666 shares during the last quarter. Northern Trust Corp lifted its stake in Sarepta Therapeutics by 3.6% during the third quarter. Northern Trust Corp now owns 425,423 shares of the biotechnology company’s stock valued at $51,570,000 after purchasing an additional 14,868 shares during the last quarter. Finally, Algert Global LLC lifted its stake in Sarepta Therapeutics by 69.3% during the third quarter. Algert Global LLC now owns 43,182 shares of the biotechnology company’s stock valued at $5,235,000 after purchasing an additional 17,670 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.